Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ghrelin Administration on Motivation and Resting Energy Expenditure in MDD
NCT06576440Completed
- Sponsor
- University Hospital Tübingen
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of human ghrelin in major depressive disorder (MDD) (2 arms), sponsored by University Hospital Tübingen. Primary endpoints: Ghrelin-induced changes in motivation, Ghrelin-induced changes in Resting Energy Expenditure and 2 more. Started Sep 2024; status: completed.
02
Drugs
human ghrelin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06576440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06576440.